2020
DOI: 10.1136/bmjophth-2019-000331
|View full text |Cite
|
Sign up to set email alerts
|

Ocular side effects of antirheumatic medications: a qualitative review

Abstract: TopicThis paper reviews the ocular side effects of medications used in the treatment of rheumatological conditions.Clinical relevanceRheumatic diseases are inflammatory conditions that may affect the skin, blood vessels, joints, muscles and internal organs. Immunosuppressive agents are often used as treatment and while powerful, they carry side effects and toxicities that need careful monitoring. Ophthalmic complications have been reported with the use of antirheumatic medications; however, there is a lack of … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
9
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 18 publications
(9 citation statements)
references
References 121 publications
0
9
0
Order By: Relevance
“…Retinal necrosis, conjunctivitis and ME have been reported as possible side effects in patients treated with Rituximab. 1 ME is a rare consequence of Rituximab infusions and very few cases are reported in the literature. [3][4][5] Details on previous cases described are summarized in Table 1.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Retinal necrosis, conjunctivitis and ME have been reported as possible side effects in patients treated with Rituximab. 1 ME is a rare consequence of Rituximab infusions and very few cases are reported in the literature. [3][4][5] Details on previous cases described are summarized in Table 1.…”
Section: Discussionmentioning
confidence: 99%
“…Retinal necrosis, conjunctivitis and ME have been reported as possible side effects in patients treated with Rituximab. 1…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“… 4 Paradoxical ophthalmologic reactions, including uveitis, sarcoid uveitis, scleritis, optic neuritis, diplopia, and visual field defects/scotomas have been reported in TNF-α inhibitors. 5 Ustekinumab (Stelara, Janssen Biotech Inc.) employs a different mechanism of action than the older anti-TNF agents. 6 It is an anti-p40 IL-12/IL-23 human immunoglobulin monoclonal antibody that reduces levels of IL-12/IL-23, which in turn downregulates multiple pro-inflammatory cytokines, such as TNF-α, IFN-γ, and IL-2.…”
Section: Discussionmentioning
confidence: 99%
“… 1 Though uncommon, ocular complications involving the optic nerve have been associated with TNF inhibitors. 2 Herein, we report a case of non-arteritic anterior ischemic optic neuropathy (NAION) as an adverse reaction to adalimumab in the treatment of HS.…”
Section: Introductionmentioning
confidence: 99%